Ahangarzadeh Shahrzad, Yousefi Alireza, Ranjbar Mohammad Mehdi, Dabiri Arezou, Zarepour Atefeh, Sadeghi Mahmoud, Heidari Elham, Mazrui Fariba, Hosseinzadeh Majid, Ataei Behrooz, Zarrabi Ali, Shariati Laleh, Haghjooy Javanmard Shaghayegh
Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran.
Razi Vaccine and Serum Research Institute, Agricultural Research, Education, and Extension Organization (AREEO), Karaj 31585-854, Iran.
J Clin Med. 2022 Oct 26;11(21):6315. doi: 10.3390/jcm11216315.
Mutations in spike glycoprotein, a critical protein of SARS-CoV-2, could directly impact pathogenicity and virulence. The D614G mutation, a non-synonymous mutation at position 614 of the spike glycoprotein, is a predominant variant circulating worldwide. This study investigated the occurrence of mutations in the crucial zone of the spike gene and the association of clinical symptoms with spike mutations in isolated viruses from Iranian patients infected with SARS-CoV-2 during the second and third waves of the COVID-19 epidemic in Isfahan, the third-largest city in Iran.
The extracted RNA from 60 nasopharyngeal samples of COVID-19 patients were subjected to cDNA synthesis and RT-PCR (in three overlapping fragments). Each patient's reverse transcriptase polymerase chain reaction (RT-PCR) products were assembled and sequenced. Information and clinical features of all sixty patients were collected, summarized, and analyzed using the GENMOD procedure of SAS 9.4.
Analysis of 60 assembled sequences identified nine nonsynonymous mutations. The D614G mutation has the highest frequency among the amino acid changes. In our study, in 31 patients (51.66%), D614G mutation was determined. For all the studied symptoms, no significant relationship was observed with the incidence of D614G mutation.
D614G, a common mutation among several of the variants of SARS-CoV-2, had the highest frequency among the studied sequences and its frequency increased significantly in the samples of the third wave compared to the samples of the second wave of the disease.
刺突糖蛋白是严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的一种关键蛋白,其突变可能直接影响致病性和毒力。D614G突变是刺突糖蛋白第614位的一个非同义突变,是全球流行的主要变异株。本研究调查了在伊朗第三大城市伊斯法罕2019冠状病毒病疫情第二波和第三波期间,从感染SARS-CoV-2的伊朗患者分离出的病毒中,刺突基因关键区域的突变情况以及临床症状与刺突突变的关联。
从60例COVID-19患者的鼻咽样本中提取的RNA进行cDNA合成和RT-PCR(三个重叠片段)。将每位患者的逆转录聚合酶链反应(RT-PCR)产物进行组装和测序。使用SAS 9.4的GENMOD程序收集、汇总和分析所有60例患者的信息和临床特征。
对60个组装序列的分析确定了9个非同义突变。在氨基酸变化中,D614G突变频率最高。在我们的研究中,31例患者(51.66%)检测到D614G突变。对于所有研究的症状,未观察到与D614G突变发生率有显著关系。
D614G是SARS-CoV-2几种变异株中的常见突变,在所研究的序列中频率最高,与疾病第二波样本相比,其频率在第三波样本中显著增加。